Roche submits Pegasys BLA

Hoffmann-La Roche submitted a BLA to the FDA for its Pegasys peginterferon alfa-2a to treat chronic hepatitis C infection in cirrhotic and non-cirrhotic patients with compensated liver disease. Pegasy...